NEW YORK (GBI Research) –
Cardiovascular surgery device suppliers must prepare for tough times ahead in America,
according to a new report by business intelligence expert GBI Research.
The new report states that instances of cardiac surgery
will fall in the US, which represents the largest national market for this
treatment, due to a growing preference for non-surgical options.
The US
is the biggest market for cardiovascular surgery devices, due to factors such
as an aging population and increasing numbers of patients with heart disease.
However, the increasing adoption of alternative, minimally invasive treatment
procedures threatens to negatively affect the growth of the cardiovascular
surgery devices market in the future.
The popularity of percutaneous coronary intervention (PCI)
and other minimally invasive interventions over surgical procedures is rising
due to patient fears of post-surgery complications, healthcare struggles to
meet strict budgets and a shortage of cardiac surgeons in the US.
Other factors such as a falling average selling price (ASP)
and cost containment pressures in developed economies will also negatively
affect the sale of cardiovascular surgery devices.
The US
contributed $688m to the cardiovascular surgery devices market in 2010,
accounting for 38% of the global market. This is forecast to decline at a CAGR
of -1.6%, to reach a market value of $616.1m in 2017. The decline of its
biggest customer means that, globally, the cardiovascular surgery devices market
is forecast to decline to $1.6 billion by 2017.
The perfusion disposables market was the largest category in
the global cardiovascular surgery devices market in 2010, accounting for a 79%
share, but even this high-demand surgical device will not escape unscathed.
Perfusion disposables alone will witness a drop in value of $100million over
the next five years, spelling bad news for manufacturers all over the world,
and reflecting the pessimistic tone overruling the broader market.
